Eli Lilly just posted one of the biggest earnings beats in pharma history — and the twist is that it happened because prices went down, not up.
Second-quarter revenue hit $22.97 billion, blowing past the $20.73 billion Wall Street expected.
Adjusted earnings came in at $8.38 per share — analysts were only banking on $6.01.
The stock jumped over 5% in premarket trading.
Here's the number that should stop you mid-scroll.
91%.
That's how much worldwide revenue for Mounjaro, Lilly's diabetes drug, grew this quarter — hitting nearly $10 billion.
Zepbound, the weight-loss version, wasn't far behind: $4.93 billion in U.S. sales alone, up 44% year-over-year.
Lilly didn't just beat guidance. It raised its own full-year forecast to $85-87 billion, up from $82-85 billion.
Normally, when a company cuts prices, revenue takes a hit.
Not here.
Lilly's U.S. prescription volume — the actual number of pills and pens going out the door — jumped 37% this quarter.
That surge more than made up for the lower price per prescription.
CEO Dave Ricks called this months ago. He predicted that cheaper prices would pull in more patients, not fewer sales.
Turns out he was right.
So what actually got cheaper?
Everyone talks about the U.S. weight-loss boom.
But look at this quarter's international numbers.
Revenue outside the U.S. jumped 80%, to $8.6 billion.
Mounjaro sales outside America grew 172%.
That's not incremental growth. That's a new market opening up in real time, mostly because Lilly is willing to accept lower prices abroad in exchange for scale.
This was also the first earnings report to include Foundayo, Lilly's newly approved obesity pill.
It brought in $98 million in its debut quarter — a hair under analyst expectations of $103 million.
Why does a pill matter so much?
Because it goes head-to-head with Novo Nordisk's rival oral GLP-1, which hit the market a few months earlier.
No needles. No fridge. No pen.
Just a daily pill — which could be the format that finally makes weight-loss drugs mainstream rather than niche.
All this cash isn't just sitting in the bank.
Lilly is on an M&A spree funded almost entirely by the obesity and diabetes windfall:
Net income for the quarter hit $7.10 billion, even after absorbing $3.03 per share in one-time deal charges tied to those acquisitions.
Strip those out, and the underlying profit picture looks even stronger than the headline suggests.
Ricks' bet, back in April, was that global GLP-1 usage would climb from roughly 20 million patients at the end of 2025 to 30 million by the end of 2026.
Three months into that window, the math is tracking.
Lower prices. Higher volume. New markets. A new pill format. Medicare finally saying yes.
Every lever that could pull more people into the GLP-1 category is now pulling at the same time.
And Lilly just showed Wall Street exactly what that looks like on a balance sheet.
That's all for now!
